论文信息 - Itraconazole, a new orally active antifungal, in the treatment of pityriasis versicolor

Itraconazole, a new orally active antifungal, in the treatment of pityriasis versicolor

Itraconazole, a new orally active triazole antifungal, has been tested in patients with pityriasis versicolor. A comparison of different dose schedules was carried out in 73 patients. A regime of 100 mg itraconazole daily for 15 days gave a 100% response rate; 200 mg daily for 5 days gave an 80% response rate. Two patients, who had received 50 mg itraconazole for 14 days, relapsed within 2 months of finishing treatment. Only two patients reported minor side‐effects.

H. Degreef | G. Cauwenbergh | J. Delescluse

[1] J. V. Cutsem,et al. Nouveaux antimycosiques: activité in vitro et in vivo , 1985 .

[2] J. V. Cutsem,et al. Les azoles antifongiques , 1984 .

[3] C. Meisel. [10-day therapy of pityriasis versicolor with ketoconazole]. , 1983, Zeitschrift fur Hautkrankheiten.

[4] H. B. Levine. Ketoconazole in the management of fungal disease. , 1982 .

[5] D. Borelli. Treatment of pityriasis versicolor with ketoconazole. , 1980, Reviews of infectious diseases.